Myriad Genetics
MYGN
201 hedge funds and large institutions have $2.31B invested in Myriad Genetics in 2021 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 70 increasing their positions, 61 reducing their positions, and 22 closing their positions.
46% more call options, than puts
Call options by funds: $4.34M | Put options by funds: $2.98M
23% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 22
15% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 61
2% more funds holding
Funds holding: 197 → 201 (+4)
1.18% more ownership
Funds ownership: 96.8% → 97.99% (+1.2%)
3% more capital invested
Capital invested by funds: $2.25B → $2.31B (+$60.6M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$32.2M |
| 2 |
Goldman Sachs
New York
|
+$25.4M |
| 3 |
JP Morgan Chase
New York
|
+$14.8M |
| 4 |
BlackRock
New York
|
+$10.8M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EARNEST Partners
Atlanta,
Georgia
|
-$28.7M |
| 2 |
D.E. Shaw & Co
New York
|
-$12M |
| 3 |
Two Sigma Investments
New York
|
-$7.85M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$7.55M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$6.5M |
MYGN Hedge Fund Activity: Q2 2021 in Review
201 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q2 2021, worth a combined $2.31B — up 2.7% from $2.25B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new MYGN positions and 22 closed out — a net gain of 5 holders — while 70 added to existing stakes and 61 trimmed.
The largest buyer was Artisan Partners, opening a new position worth an estimated $32.2M. The largest seller was EARNEST Partners, cutting an estimated $28.7M.
- 201 institutional investors held Myriad Genetics (MYGN) as of Q2 2021, up from 197 in Q1 2021.
- Funds reported $2.31B of Myriad Genetics stock for Q2 2021, up 2.7% quarter-over-quarter.
- 27 funds opened new Myriad Genetics positions in Q2 2021 and 22 closed out, a net change of +5 holders.
- The largest Myriad Genetics buyer in Q2 2021 was Artisan Partners, an estimated $32.2M added.
- The largest Myriad Genetics seller in Q2 2021 was EARNEST Partners, an estimated $28.7M sold.
Based on aggregated 13F filings for Q2 2021.